{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:21:09Z","timestamp":1747207269310,"version":"3.40.5"},"reference-count":75,"publisher":"Bentham Science Publishers Ltd.","issue":"44","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Global dissemination of antimicrobial resistance (AMR) not only poses a significant threat to human\nhealth, food security, and social development but also results in millions of deaths each year. In Gram-negative\nbacteria, the primary mechanism of resistance to \u03b2-lactam antibiotics is the production of \u03b2-lactamases, one of\nwhich is carbapenem-hydrolyzing \u03b2-lactamases known as carbapenemases. As a general scheme, these enzymes\nare divided into Ambler class A, B, C, and D based on their protein sequence homology. Class B \u03b2-lactamases\nare also known as metallo-\u03b2-lactamases (MBLs). The incidence of recovery of bacteria expressing metallo-\u03b2-\nlactamases (MBLs) has increased dramatically in recent years, almost reaching a pandemic proportion. MBLs\ncan be further divided into three subclasses (B1, B2, and B3) based on the homology of protein sequences as\nwell as the differences in zinc coordination. The development of inhibitors is one effective strategy to suppress\nthe activities of MBLs and restore the activity of \u03b2-lactam antibiotics. Although thousands of MBL inhibitors\nhave been reported, none have been approved for clinical use. This review describes the clinical application potential\nof peptide-based drugs that exhibit inhibitory activity against MBLs identified in past decades. In this\nreport, peptide-based inhibitors of MBLs are divided into several groups based on the mode of action, highlighting\ncompounds of promising properties that are suitable for further advancement. We discuss how traditional\ncomputational tools, such as in silico screening and molecular docking, along with new methods, such as\ndeep learning and machine learning, enable a more accurate and efficient design of peptide-based inhibitors of\nMBLs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612828666220929154255","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T07:08:57Z","timestamp":1664521737000},"page":"3538-3545","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of Peptide-based Metallo-\u03b2-lactamase Inhibitors as a New Strategy to\nCombat Antimicrobial Resistance: A Mini-review"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3526-7808","authenticated-orcid":true,"given":"Sheng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases\nand Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong\nKong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2365-4416","authenticated-orcid":true,"given":"Qipeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Anhui Provincial Key Laboratory of Molecular Enzymology and Mechanism of Major Diseases and Key Laboratory of Biomedicine in Gene Diseases and Health of Anhui Higher Education Institutes, College of Life Sciences, Anhui Normal University, Wuhu, Anhui, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9817-3898","authenticated-orcid":true,"given":"Ping","family":"Zeng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-5289","authenticated-orcid":true,"given":"Edward Wai","family":"Chi Chan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases\nand Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon, Hong\nKong"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrmicro3380","volume":"13","author":"Blair J.M.A.","year":"2015","unstructured":"Blair J.M.A.; Webber M.A.; Baylay A.J.; Ogbolu D.O.; Piddock L.J.V.; Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 2015,13(1),42-51","journal-title":"Nat Rev Microbiol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41579-021-00649-x","volume":"20","author":"Larsson D.G.J.","year":"2022","unstructured":"Larsson D.G.J.; Flach C.F.; Antibiotic resistance in the environment. Nat Rev Microbiol 2022,20(5),257-269","journal-title":"Nat Rev Microbiol"},{"key":"ref=3","author":"Ramirez J.A.","year":"2019","unstructured":"Ramirez J.A.;  Overview of community-acquired pneumonia in adults 2019","journal-title":"Overview of community-acquired pneumonia in adults"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fmed.2020.00420","volume":"7","author":"Manohar P.","year":"2020","unstructured":"Manohar P.; Loh B.; Nachimuthu R.; Hua X.; Welburn S.C.; Leptihn S.; Secondary bacterial infections in patients with viral pneumonia. Front Med (Lausanne) 2020,7,420","journal-title":"Front Med (Lausanne)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0140-6736(19)31882-3","volume":"394","author":"Lange C.","year":"2019","unstructured":"Lange C.; Dheda K.; Chesov D.; Mandalakas A.M.; Udwadia Z.; Horsburgh C.R.; Management of drug-resistant tuberculosis. Lancet 2019,394(10202),953-966","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12879-020-4901-7","volume":"20","author":"Goldstein E.","year":"2020","unstructured":"Goldstein E.; Lipsitch M.; The relation between prescribing of different antibiotics and rates of mortality with sepsis in US adults. BMC Infect Dis 2020,20(1),169","journal-title":"BMC Infect Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Murray C.J.L.","year":"2022","unstructured":"Murray C.J.L.; Ikuta K.S.; Sharara F.; Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022,399(10325),629-655","journal-title":"Lancet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/molecules25061340","volume":"25","author":"Breijyeh Z.","year":"2020","unstructured":"Breijyeh Z.; Jubeh B.; Karaman R.; Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. Molecules 2020,25(6),1340","journal-title":"Molecules"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1093\/cid\/ciw829","volume":"64","author":"Doi Y.","year":"2017","unstructured":"Doi Y.; Bonomo R.A.; Hooper D.C.; Gram-negative bacterial infections: Research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis 2017,64(Suppl. 1),S30-S35","journal-title":"Clin Infect Dis"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1128\/9781555819286.ch17","author":"Munita J.M.","year":"2016","unstructured":"Munita J.M.; Arias C.A.; Mechanisms of antibiotic resistance. Virulence Mechanisms of Bacterial Pathogens 2016,481-511","journal-title":"Virulence Mechanisms of Bacterial Pathogens"},{"key":"ref=11","author":"King D.T.","year":"2017","unstructured":"King D.T.; Sobhanifar S.; Strynadka N.C.; Gotte M.; The mechanisms of resistance to b-lactam antibiotics. In: Handbook of Antimicrobial Resistance 2017","journal-title":"In: Handbook of Antimicrobial Resistance"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.4155\/fmc-2016-0076","volume":"8","author":"Bush K.","year":"2016","unstructured":"Bush K.; Overcoming &#x3B2;-lactam resistance in gram-negative pathogens. Future Med Chem 2016,8(9),921-924","journal-title":"Future Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e01076","DOI":"10.1128\/AAC.01076-18","volume":"62","author":"Bush K.","year":"2018","unstructured":"Bush K.; Past and present perspectives on &#x3B2;-lactamases. Antimicrob Agents Chemother 2018,62(10),e01076-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1098\/rstb.1980.0049","volume":"289","author":"Ambler R.P.","year":"1980","unstructured":"Ambler R.P.; The structure of &#x3B2;-lactamases. Philos Trans R Soc Lond B Biol Sci 1980,289(1036),321-331","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/222024a0","volume":"222","author":"Ambler R.P.","year":"1969","unstructured":"Ambler R.P.; Meadway R.J.; Chemical structure of bacterial penicillinases. Nature 1969,222(5188),24-26","journal-title":"Nature"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.drup.2004.02.003","volume":"7","author":"Hall B.G.","year":"2004","unstructured":"Hall B.G.; Barlow M.; Evolution of the serine &#x3B2;-lactamases: Past, present and future. Drug Resist Updat 2004,7(2),111-123","journal-title":"Drug Resist Updat"},{"key":"ref=17","first-page":"130","volume":"19","author":"Salahuddin P.","year":"2018","unstructured":"Salahuddin P.; Kumar A.; Khan A.U.; Structure, function of serine and metallo-&#x3B2;-lactamases and their inhibitors. Curr Protein Pept Sci 2018,19(2),130-144","journal-title":"Curr Protein Pept Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2012.06796.x","volume":"1277","author":"Palzkill T.","year":"2013","unstructured":"Palzkill T.; Metallo-&#x3B2;-lactamase structure and function. Ann N Y Acad Sci 2013,1277(1),91-104","journal-title":"Ann N Y Acad Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1128\/AAC.35.1.147","volume":"35","author":"Watanabe M.","year":"1991","unstructured":"Watanabe M.; Iyobe S.; Inoue M.; Mitsuhashi S.; Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991,35(1),147-151","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1128\/AAC.43.7.1584","volume":"43","author":"Lauretti L.","year":"1999","unstructured":"Lauretti L.; Riccio M.L.; Mazzariol A.; Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 1999,43(7),1584-1590","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"5046","DOI":"10.1128\/AAC.00774-09","volume":"53","author":"Yong D.","year":"2009","unstructured":"Yong D.; Toleman M.A.; Giske C.G.; Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009,53(12),5046-5054","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","volume":"64","author":"Boyd S.E.","year":"2020","unstructured":"Boyd S.E.; Livermore D.M.; Hooper D.C.; Hope W.W.; Metallo-&#x3B2;-lactamases: Structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob Agents Chemother 2020,64(10),e00397-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","volume":"10","author":"Han R.","year":"2020","unstructured":"Han R.; Shi Q.; Wu S.; Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenemresistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol 2020,10,314","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","volume":"17","author":"Bush K.","year":"2019","unstructured":"Bush K.; Bradford P.A.; Interplay between &#x3B2;-lactamases and new &#x3B2;-lactamase inhibitors. Nat Rev Microbiol 2019,17(5),295-306","journal-title":"Nat Rev Microbiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","volume":"23","author":"Drawz S.M.","year":"2010","unstructured":"Drawz S.M.; Bonomo R.A.; Three decades of &#x3B2;-lactamase inhibitors. Clin Microbiol Rev 2010,23(1),160-201","journal-title":"Clin Microbiol Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","volume":"288","author":"Ehmann D.E.","year":"2013","unstructured":"Ehmann D.E.; Jahi\u0107 H.; Ross P.L.; Kinetics of avibactam inhibition against class A, C, and D &#x3B2;-lactamases. J Biol Chem 2013,288(39),27960-27971","journal-title":"J Biol Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1128\/AAC.05927-11","volume":"56","author":"Hirsch E.B.","year":"2012","unstructured":"Hirsch E.B.; Ledesma K.R.; Chang K.T.; Schwartz M.S.; Motyl M.R.; Tam V.H.; In vitro activity of MK-7655, a novel &#x3B2;-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2012,56(7),3753-3757","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","volume":"58","author":"Hecker S.J.","year":"2015","unstructured":"Hecker S.J.; Reddy K.R.; Totrov M.; Discovery of a cyclic boronic acid &#x3B2;-lactamase inhibitor (RPX7009) with utility vs. class A serine carbapenemases. J Med Chem 2015,58(9),3682-3692","journal-title":"J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e00174","DOI":"10.1128\/AAC.00174-18","volume":"62","author":"Papp-Wallace K.M.","year":"2018","unstructured":"Papp-Wallace K.M.; Barnes M.D.; Alsop J.; Relebactam is a potent inhibitor of the KPC-2 &#x3B2;-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae. Antimicrob Agents Chemother 2018,62(6),e00174-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/jac\/dkp197","volume":"64","author":"Stachyra T.","year":"2009","unstructured":"Stachyra T.; Levasseur P.; P&#xE9;chereau M.C.; In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009,64(2),326-329","journal-title":"J Antimicrob Chemother"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e01443","DOI":"10.1128\/AAC.01443-17","volume":"61","author":"Lomovskaya O.","year":"2017","unstructured":"Lomovskaya O.; Sun D.; Rubio-Aparicio D.; Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017,61(11),e01443-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"7957","DOI":"10.1021\/acs.chemrev.1c00138","volume":"121","author":"Bahr G.","year":"2021","unstructured":"Bahr G.; Gonz&#xE1;lez L.J.; Vila A.J.; Metallo-&#x3B2;-lactamases in the age of multidrug resistance: From structure and mechanism to evolution, dissemination, and inhibitor design. Chem Rev 2021,121(13),7957-8094","journal-title":"Chem Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","volume":"20","author":"Muttenthaler M.","year":"2021","unstructured":"Muttenthaler M.; King G.F.; Adams D.J.; Alewood P.F.; Trends in peptide drug discovery. Nat Rev Drug Discov 2021,20(4),309-325","journal-title":"Nat Rev Drug Discov"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"Wang L.","year":"2022","unstructured":"Wang L.; Wang N.; Zhang W.; Therapeutic peptides: Current applications and future directions. Signal Transduct Target Ther 2022,7(1),48","journal-title":"Signal Transduct Target Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","volume":"61","author":"Henninot A.","year":"2018","unstructured":"Henninot A.; Collins J.C.; Nuss J.M.; The current state of peptide drug discovery: Back to the future? J Med Chem 2018,61(4),1382-1414","journal-title":"J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S1473-3099(20)30327-3","volume":"20","author":"Magana M.","year":"2020","unstructured":"Magana M.; Pushpanathan M.; Santos A.L.; The value of antimicrobial peptides in the age of resistance. Lancet Infect Dis 2020,20(9),e216-e230","journal-title":"Lancet Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/cmdc.201900364","volume":"14","author":"Zeng P.","year":"2019","unstructured":"Zeng P.; Xu C.; Cheng Q.; Phenol\u2010soluble\u2010modulin\u2010inspired amphipathic peptides have bactericidal activity against multidrug\u2010resistant bacteria. ChemMedChem 2019,14(16),1547-1559","journal-title":"ChemMedChem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"R14","DOI":"10.1016\/j.cub.2015.11.017","volume":"26","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Gallo R.L.; Antimicrobial peptides. Curr Biol 2016,26(1),R14-R19","journal-title":"Curr Biol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14756366.2017.1344235","volume":"32","author":"Naas T.","year":"2017","unstructured":"Naas T.; Oueslati S.; Bonnin R.A.; Beta-lactamase database (BLDB) \u2013 structure and function. J Enzyme Inhib Med Chem 2017,32(1),917-919","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1021\/acsinfecdis.8b00137","volume":"4","author":"Schnaars C.","year":"2018","unstructured":"Schnaars C.; Kildahl-Andersen G.; Prandina A.; Synthesis and preclinical evaluation of TPA-based zinc chelators as metallo-&#x3B2;-lactamase inhibitors. ACS Infect Dis 2018,4(9),1407-1422","journal-title":"ACS Infect Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1039\/C8MD00578H","volume":"10","author":"Kildahl-Andersen G.","year":"2019","unstructured":"Kildahl-Andersen G.; Schnaars C.; Prandina A.; Synthesis and biological evaluation of zinc chelating compounds as metallo-&#x3B2;-lactamase inhibitors. MedChemComm 2019,10(4),528-537","journal-title":"MedChemComm"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/biom4020419","volume":"4","author":"Pace N.","year":"2014","unstructured":"Pace N.; Weerapana E.; Zinc-binding cysteines: Diverse functions and structural motifs. Biomolecules 2014,4(2),419-434","journal-title":"Biomolecules"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0968-0896(00)00257-1","volume":"9","author":"Bounaga S.","year":"2001","unstructured":"Bounaga S.; Galleni M.; Laws A.P.; Page M.I.; Cysteinyl peptide inhibitors of Bacillus cereus zinc &#x3B2;-lactamase. Bioorg Med Chem 2001,9(2),503-510","journal-title":"Bioorg Med Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1016\/j.bmcl.2006.07.001","volume":"16","author":"Sun Q.","year":"2006","unstructured":"Sun Q.; Law A.; Crowder M.W.; Geysen H.M.; Homo-cysteinyl peptide inhibitors of the L1 metallo-&#x3B2;-lactamase, and SAR as determined by combinatorial library synthesis. Bioorg Med Chem Lett 2006,16(19),5169-5175","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e0177293","DOI":"10.1371\/journal.pone.0177293","volume":"12","author":"Shen B.","year":"2017","unstructured":"Shen B.; Zhu C.; Gao X.; Liu G.; Song J.; Yu Y.; Oligopeptides as full-length New Delhi metallo-&#x3B2;-lactamase-1 (NDM-1) inhibitors. PLoS One 2017,12(5),e0177293","journal-title":"PLoS One"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1073\/pnas.93.3.1221","volume":"93","author":"Fehlbaum P.","year":"1996","unstructured":"Fehlbaum P.; Bulet P.; Chernysh S.; Structure-activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides. Proc Natl Acad Sci USA 1996,93(3),1221-1225","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1038\/s41467-019-11503-3","volume":"10","author":"Ma B.","year":"2019","unstructured":"Ma B.; Fang C.; Lu L.; The antimicrobial peptide thanatin disrupts the bacterial outer membrane and inactivates the NDM-1 metallo-&#x3B2;-lactamase. Nat Commun 2019,10(1),3517","journal-title":"Nat Commun"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fmicb.2020.00909","volume":"11","author":"Moura E.C.C.M.","year":"2020","unstructured":"Moura E.C.C.M.; Baeta T.; Romanelli A.; Thanatin impairs lipopolysaccharide transport complex assembly by targeting LptC\u2013LptA interaction and decreasing LptA stability. Front Microbiol 2020,11,909","journal-title":"Front Microbiol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.3390\/molecules25245797","volume":"25","author":"Selvaraju G.","year":"2020","unstructured":"Selvaraju G.; Leow T.C.; Salleh A.B.; Normi Y.M.; Design and characterisation of inhibitory peptides against Bleg1_2478, an evolutionary divergent B3 metallo-&#x3B2;-lactamase. Molecules 2020,25(24),5797","journal-title":"Molecules"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e2012800118","DOI":"10.1073\/pnas.2012800118","volume":"118","author":"Mulligan V.K.","year":"2021","unstructured":"Mulligan V.K.; Workman S.; Sun T.; Computationally designed peptide macrocycle inhibitors of New Delhi metallo-&#x3B2;-lactamase 1. PNAS 2021,118(12),e2012800118","journal-title":"PNAS"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nature19791","volume":"538","author":"Bhardwaj G.","year":"2016","unstructured":"Bhardwaj G.; Mulligan V.K.; Bahl C.D.; Accurate de novo design of hyperstable constrained peptides. Nature 2016,538(7625),329-335","journal-title":"Nature"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.aap7577","volume":"358","author":"Hosseinzadeh P.","year":"2017","unstructured":"Hosseinzadeh P.; Bhardwaj G.; Mulligan V.K.; Comprehensive computational design of ordered peptide macrocycles. Science 2017,358(6369),1461-1466","journal-title":"Science"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.bbagen.2015.07.012","volume":"1850","author":"Rotondo C.M.","year":"2015","unstructured":"Rotondo C.M.; Marrone L.; Goodfellow V.J.; Arginine-containing peptides as potent inhibitors of VIM-2 metallo-&#x3B2;-lactamase. Biochim Biophys Acta, Gen Subj 2015,1850(11),2228-2238","journal-title":"Biochim Biophys Acta, Gen Subj"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/BJ20121305","volume":"450","author":"Sohier J.S.","year":"2013","unstructured":"Sohier J.S.; Laurent C.; Chevign&#xE9; A.; Allosteric inhibition of VIM metallo-&#x3B2;-lactamases by a camelid nanobody. Biochem J 2013,450(3),477-486","journal-title":"Biochem J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1128\/AAC.45.10.2807-2812.2001","volume":"45","author":"Conrath K.E.","year":"2001","unstructured":"Conrath K.E.; Lauwereys M.; Galleni M.; &#x3B2;-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother 2001,45(10),2807-2812","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.3390\/molecules25194453","volume":"25","author":"Ben Abderrazek R.","year":"2020","unstructured":"Ben Abderrazek R.; Chammam S.; Ksouri A.; Inhibitory potential of polyclonal camel antibodies against new delhi metallo-&#x3B2;-lactamase-1 (NDM-1). Molecules 2020,25(19),4453","journal-title":"Molecules"},{"key":"ref=57","first-page":"782","volume":"72","author":"Sully E.K.","year":"2017","unstructured":"Sully E.K.; Geller B.L.; Li L.; Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo. J Antimicrob Chemother 2017,72(3),782-790","journal-title":"J Antimicrob Chemother"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1128\/AAC.00917-08","volume":"53","author":"Mellbye B.L.","year":"2009","unstructured":"Mellbye B.L.; Puckett S.E.; Tilley L.D.; Iversen P.L.; Geller B.L.; Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against Escherichia coli in vitro and in vivo. Antimicrob Agents Chemother 2009,53(2),525-530","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1086\/652807","volume":"201","author":"Greenberg D.E.","year":"2010","unstructured":"Greenberg D.E.; Marshall-Batty K.R.; Brinster L.R.; Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis 2010,201(12),1822-1830","journal-title":"J Infect Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fmicb.2016.00373","volume":"7","author":"Readman J.B.","year":"2016","unstructured":"Readman J.B.; Dickson G.; Coldham N.G.; Translational inhibition of CTX-M extended spectrum &#x3B2;-lactamase in clinical strains of Escherichia coli by synthetic antisense oligonucleotides partially restores sensitivity to cefotaxime. Front Microbiol 2016,7,373","journal-title":"Front Microbiol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"dkaa140","DOI":"10.1093\/jac\/dkaa140","volume":"75","author":"Wang X.","year":"2020","unstructured":"Wang X.; Wang Y.; Ling Z.; Peptide nucleic acid restores colistin susceptibility through modulation of MCR-1 expression in Escherichia coli. J Antimicrob Chemother 2020,75(8),dkaa140","journal-title":"J Antimicrob Chemother"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e01315","DOI":"10.1128\/mBio.01315-17","volume":"8","author":"Daly S.M.","year":"2017","unstructured":"Daly S.M.; Sturge C.R.; Felder-Scott C.F.; Geller B.L.; Greenberg D.E.; MCR-1 inhibition with peptide-conjugated phosphorodiamidate morpholino oligomers restores sensitivity to polymyxin in Escherichia coli. MBio 2017,8(6),e01315-e01317","journal-title":"MBio"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1093\/jac\/dkaa242","volume":"75","author":"Kazi M.I.","year":"2020","unstructured":"Kazi M.I.; Perry B.W.; Card D.C.; Discovery and characterization of New Delhi metallo-&#x3B2;-lactamase-1 inhibitor peptides that potentiate meropenem-dependent killing of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2020,75(10),2843-2851","journal-title":"J Antimicrob Chemother"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e00698","DOI":"10.1128\/AEM.00698-18","volume":"84","author":"Somboro A.M.","year":"2018","unstructured":"Somboro A.M.; Osei Sekyere J.; Amoako D.G.; Essack S.Y.; Bester L.A.; Diversity and proliferation of metallo-&#x3B2;-lactamases: A clarion call for clinically effective metallo-&#x3B2;-lactamase inhibitors. Appl Environ Microbiol 2018,84(18),e00698-e18","journal-title":"Appl Environ Microbiol"},{"key":"ref=65","author":"Mojica M.F.","year":"2021","unstructured":"Mojica M.F.; Rossi M-A.; Vila A.J.; Bonomo R.A.; The urgent need for metallo-&#x3B2;-lactamase inhibitors: An unattended global threat. Lancet Infect Dis 2021","journal-title":"Lancet Infect Dis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"16124","DOI":"10.1074\/jbc.M116.719005","volume":"291","author":"Montagner C.","year":"2016","unstructured":"Montagner C.; Nigen M.; Jacquin O.; The role of active site flexible loops in catalysis and of zinc in conformational stability of Bacillus cereus 569\/H\/9 &#x3B2;-lactamase. J Biol Chem 2016,291(31),16124-16137","journal-title":"J Biol Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1039\/C4SC01752H","volume":"6","author":"Brem J.","year":"2015","unstructured":"Brem J.; Struwe W.B.; Rydzik A.M.; Studying the active-site loop movement of the S&#xE3;o Paolo metallo-&#x3B2;-lactamase-1. Chem Sci (Camb) 2015,6(2),956-963","journal-title":"Chem Sci (Camb)"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e01579","DOI":"10.1128\/AAC.01579-18","volume":"62","author":"Zhang H.","year":"2018","unstructured":"Zhang H.; Ma G.; Zhu Y.; Active-site conformational fluctuations promote the enzymatic activity of NDM-1. Antimicrob Agents Chemother 2018,62(11),e01579-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/AABC.S105289","volume":"9","author":"de Ruyck J.","year":"2016","unstructured":"de Ruyck J.; Brysbaert G.; Blossey R.; Lensink M.; Molecular docking as a popular tool in drug design, an in silico travel. Adv Appl Bioinform Chem 2016,9,1-11","journal-title":"Adv Appl Bioinform Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.2174\/1381612822666160414142530","volume":"22","author":"Haga J.H.","year":"2016","unstructured":"Haga J.H.; Ichikawa K.; Date S.; Ichikawa K.; Virtual screening techniques and current computational infrastructures. Curr Pharm Des 2016,22(23),3576-3584","journal-title":"Curr Pharm Des"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1478-5382(03)02359-X","volume":"1","author":"Seifert M.H.J.","year":"2003","unstructured":"Seifert M.H.J.; Wolf K.; Vitt D.; Virtual high-throughput in silico screening. BIOSILICO 2003,1(4),143-149","journal-title":"BIOSILICO"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"9221","DOI":"10.1039\/D1SC01713F","volume":"12","author":"Capecchi A.","year":"2021","unstructured":"Capecchi A.; Cai X.; Personne H.; K&#xF6;hler T.; van Delden C.; Reymond J.L.; Machine learning designs non-hemolytic antimicrobial peptides. Chem Sci (Camb) 2021,12(26),9221-9232","journal-title":"Chem Sci (Camb)"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/biom11030471","volume":"11","author":"Wang C.","year":"2021","unstructured":"Wang C.; Garlick S.; Zloh M.; Deep learning for novel antimicrobial peptide design. Biomolecules 2021,11(3),471","journal-title":"Biomolecules"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"16581","DOI":"10.1038\/s41598-020-73644-6","volume":"10","author":"Plisson F.","year":"2020","unstructured":"Plisson F.; Ram&#xED;rez-S&#xE1;nchez O.; Mart&#xED;nez-Hern&#xE1;ndez C.; Machine learning-guided discovery and design of non-hemolytic peptides. Sci Rep 2020,10(1),16581","journal-title":"Sci Rep"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.2174\/1381612826666201102105827","volume":"27","author":"Charoenkwan P.","year":"2021","unstructured":"Charoenkwan P.; Anuwongcharoen N.; Nantasenamat C.; Hasan M.M.; Shoombuatong W.; In silico approaches for the prediction and analysis of antiviral peptides: A review. Curr Pharm Des 2021,27(18),2180-2188","journal-title":"Curr Pharm Des"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220929154255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209315\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1381612828666220929154255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T04:14:28Z","timestamp":1691727268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209315\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":75,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612828666220929154255","relation":{},"ISSN":["1381-6128"],"issn-type":[{"type":"print","value":"1381-6128"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}